0 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Andrew Cheng
Manifold Bio
2 followers
eGenesis
1 follower
School District of Philadelphia
4 followers
Mentor Collective
3 followers
Tessera Therapeutics
2 followers
Septerna
2 followers
FieldGuide
2 followers
89bio
2 followers
Neogene Therapeutics
2 followers
SolarBioTech
2 followers
Thurgood Marshall College Fund
1 follower
Explore companies